Advancing Science and Medicine
for a Better Life
Radella Pharmaceuticals
Radella Pharmaceuticals is dedicated to creating groundbreaking drugs that address the root causes of severe and underserved diseases.
Developing a Novel Mechanism of Action
to Address Difficult-to-Treat Diseases
Radella Pharma is a privately-backed biotech company developing transformative therapies in cardiometabolic disease and beyond. We are singularly focused on delivering curative solutions to patients and bettering human health.
Our novel MOA targets an underlying physiological pathway relevant to several major underserved diseases. This innovative approach is distinct from current therapeutic modalities in diabetes and obesity, which focus on suppressing appetite and stimulating insulin production.
By disrupting a specific protein-protein interaction involving targets that are well-understood to play a role in enhancing insulin sensitivity and energy expenditure, we enable a true disease-modifying approach.
Radella is initially exploring therapies in diabetes and obesity. Our platform shows promise for further development as a safe and effective solution in other high-value markets with high unmet medical need, including atherosclerosis, dementia, and fatty liver disease.
Differentiated MOA Unlocks Significant Potential Value
Radella's approach regulates relevant pathways to address the underlying causes of poor metabolic function and unlocks a curative solution for patients. Our non-clinical studies demonstrate our ability to:
-
Improve insulin sensitivity
-
Stimulate energy expenditure
-
Preserve lean mass
-
Improve both safety/efficacy and longevity/durability
Our approach targets a mechanism distinct from incretins, and unlocks the potential for our drugs to not only be used as a primary therapy for patients living with diabetes and obesity, but also in combination with existing solutions to afford these patients the most optimal treatment options.
High Value Markets
Radella Pharma is focused on becoming a leader in the fight against diabetes and obesity. With an estimated 540 million people worldwide living with diabetes, the disease remains a significant burden on human health with an urgent need for innovative solutions beyond symptom management. Our research and development efforts are guided by the understanding that tackling the underlying mechanisms driving these diseases is essential to effecting lasting change.
Nearly 80% of patients diagnosed with Type 2 diabetes are overweight or obese, underscoring the substantial overlap between these patient populations and the urgent need for transformative therapies that address the root cause of cardiometabolic disease.
We believe our unique approach represents the potential to introduce an insulin sensitizer to the market and give patients a cure that allows them to live healthier, fuller lives unencumbered by their disease.